Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Subcutaneous Semaglutide 2.4 mg Once-weekly in Subjects With Obesity and Prediabetes

NCT05040971 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT05040971
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05040971 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Subcutaneous Semaglutide 2.4 mg Once-weekly in Subjects With Obesity and Prediabetes
Lead sponsor
Novo Nordisk A/S
Phase
Phase 3
Overall status
Completed
Start date
September 6, 2021
Completion date
July 14, 2023
Enrollment
207 (actual)
Sites
43

Conditions

As the registry lists them; a condition with its own page is linked.

obesity